{"id":129274,"date":"2026-09-11T06:29:07","date_gmt":"2026-09-11T06:29:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/129274\/"},"modified":"2026-09-11T06:29:07","modified_gmt":"2026-09-11T06:29:07","slug":"novartis-investors-turn-spotlight-on-ma-after-trial-setbacks-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/129274\/","title":{"rendered":"Novartis investors turn spotlight on M&#038;A after trial setbacks"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">LONDON\/ZURICH, Sept 11 (Reuters) &#8211; Novartis investors are set to step up scrutiny of the Swiss group&#8217;s dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Eight shareholders told Reuters that muscle-wasting disorder drug del-desiran&#8217;s \u200cfailure in a late-stage study, the second major trial setback for Novartis in days, raised questions over last year&#8217;s $12 billion Avidity purchase and other acquisitions.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis shares slumped \u200c11% in one day this week, wiping nearly $30 billion off its market value and all the gains made since the start of the year after the del-desiran results.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">CEO Vas Narasimhan, who has a strong track record on \u200bshareholder returns, now faces investor concern over how he plans to steer Novartis through looming patent expiries.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;It&#8217;s going to take a while for confidence to return,&#8221; said Gillian Hollenstein, lead manager at Point Capital Navigator Fund, which has shares in Novartis and rival Roche.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;They would have been better off doing some more smaller acquisitions, bolt-on ones rather than trying to hit it out of the park,&#8221; Hollenstein added.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Some said Novartis remained on a firm footing, with promising drugs such as remibrutinib in the pipeline.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Narasimhan, who has committed more than $30 billion in the last three years on acquisitions \u200cand partnerships, told investors at the time that Avidity was an &#8220;appropriate \u2060risk&#8221;.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">There are currently no plans to change the company&#8217;s approach towards M&amp;A or business development, a source familiar with the matter told Reuters.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">SCRUTINY OF M&amp;A PROCESS  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Artisan Partners, a major Novartis shareholder, called for a shake-up of the board to address M&amp;A oversight, while supporting Narasimhan, who became \u2060CEO in 2018 and has now been at the helm longer than his predecessor Joe Jimenez.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The 50-year-old American has navigated post-COVID-19 pandemic shifts and mounting U.S. pressure to cut prices, first under the Biden administration and then under President Donald Trump, who has threatened Swiss businesses with tariffs.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Michael Hannig, portfolio manager at Novartis shareholder DJE Kapital, said that to rebuild confidence the drugmaker should pursue deals in the $5 \u200bbillion \u200bto $10 billion range for late-stage assets or drugs nearing approval.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">That could help address looming patent expiries, though \u200bdue diligence was needed to ensure a strategic fit and the quality \u200cof clinical evidence, he said.  <\/p>\n<p>     Story Continues  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;Larger transactions will likely be assessed carefully by investors considering the mixed market reception to several prior deals,&#8221; Hannig said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Another of Novartis&#8217; top-15 shareholders, speaking on condition of anonymity, said investors would be more critical of future acquisitions.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">TOO EARLY TO CALL FOR HEADS TO ROLL  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis points to strong returns under Narasimhan.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Its shares are up more than 60% and have delivered total returns of some 120% including reinvested dividends since he took over, compared with about 108% for Swiss rival Roche and some 200% for British-based drugmaker AstraZeneca.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Daniel Bolanowski, portfolio manager at investor Arctic Asset Management, said the scale of the share sell-off suggested investors were questioning more than the value of del-desiran, with a &#8220;deeper trust issue&#8221; about business development.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">But \u200cNovartis still has two other Avidity drugs, del-zota and del-brax, in development that could generate revenue, Bolanowski \u200bsaid, adding: &#8220;It&#8217;s a little bit premature to call for heads at this point&#8221;.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Narasimhan&#8217;s M&amp;A strategy would now be viewed \u200bmore critically, investors said. Generics unit Sandoz, spun off in 2023, has also \u200bfar outperformed Novartis, some analysts said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">However, while the del-desiran flop was painful, the HARBOR study assessing it was designed before Novartis bought Avidity, said \u200cGuy Bettschart-Ghassabi, healthcare analyst at Novartis investor Bellevue Asset Management. He noted \u200bmyotonic dystrophy, the disease it targeted, is challenging.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">He \u200breaffirmed his confidence in the company&#8217;s management.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Markus Manns, portfolio manager at Novartis shareholder Union Investment, said the two failures were unfortunate but were within normal drug development success probabilities.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The next major test for Novartis is detailed data for remibrutinib in relapsing multiple sclerosis, due at a medical meeting in October. While the oral drug met the \u200bmain goals of two late-stage studies, investors are waiting for \u200cfuller evidence on efficacy, disability progression and safety.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;They have to work harder to fulfill their post-2030 goals. But it&#8217;s in the same camp as most other \u200bpharma companies,&#8221; Manns said, adding that while the M&amp;A strategy needed to be better, Narasimhan had a strong vision and had boosted Novartis value.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by Bhanvi \u200bSatija, Oliver Hirt and Marleen Kaesebier; Editing by Adam Jourdan, Dave Graham and Alexander Smith)  <\/p>\n","protected":false},"excerpt":{"rendered":"By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON\/ZURICH, Sept 11 (Reuters) &#8211; Novartis investors are set to&hellip;\n","protected":false},"author":2,"featured_media":129275,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[13808,1350,3343,10021,206,9827],"class_list":["post-129274","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-avidity","tag-investors","tag-mergers-and-acquisitions","tag-narasimhan","tag-novartis","tag-vas-narasimhan"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117250999087947878","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=129274"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/129275"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=129274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=129274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=129274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}